DK3248462T3 - Genmodificering af mus til fremstilling af kimære antifstoffer - Google Patents

Genmodificering af mus til fremstilling af kimære antifstoffer Download PDF

Info

Publication number
DK3248462T3
DK3248462T3 DK17178088.5T DK17178088T DK3248462T3 DK 3248462 T3 DK3248462 T3 DK 3248462T3 DK 17178088 T DK17178088 T DK 17178088T DK 3248462 T3 DK3248462 T3 DK 3248462T3
Authority
DK
Denmark
Prior art keywords
mice
chimeric antibodies
genetic modification
produce chimeric
produce
Prior art date
Application number
DK17178088.5T
Other languages
English (en)
Inventor
Larry Green
Hiroaki Shizuya
Original Assignee
Ablexis Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44712850&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK3248462(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Ablexis Llc filed Critical Ablexis Llc
Application granted granted Critical
Publication of DK3248462T3 publication Critical patent/DK3248462T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/46—Hybrid immunoglobulins
    • C07K16/461—Igs containing Ig-regions, -domains or -residues form different species
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A01K67/0275—Genetically modified vertebrates, e.g. transgenic
    • A01K67/0278—Knock-in vertebrates, e.g. humanised vertebrates
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/8509—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells for producing genetically modified animals, e.g. transgenic
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2207/00—Modified animals
    • A01K2207/15—Humanized animals
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A01K2217/052—Animals comprising random inserted nucleic acids (transgenic) inducing gain of function
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/07—Animals genetically altered by homologous recombination
    • A01K2217/072—Animals genetically altered by homologous recombination maintaining or altering function, i.e. knock in
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2227/00—Animals characterised by species
    • A01K2227/10—Mammal
    • A01K2227/105—Murine
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2267/00—Animals characterised by purpose
    • A01K2267/01—Animal expressing industrially exogenous proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C07K2317/14—Specific host cells or culture conditions, e.g. components, pH or temperature
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/522—CH1 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/53—Hinge
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/64—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising a combination of variable region and constant region components
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • C12N2510/02—Cells for production

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Environmental Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK17178088.5T 2010-03-31 2011-03-31 Genmodificering af mus til fremstilling af kimære antifstoffer DK3248462T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US31969010P 2010-03-31 2010-03-31
US36130210P 2010-07-02 2010-07-02
EP11763476.6A EP2553100B1 (en) 2010-03-31 2011-03-31 Genetic engineering of non-human animals for the production of chimeric antibodies

Publications (1)

Publication Number Publication Date
DK3248462T3 true DK3248462T3 (da) 2024-05-06

Family

ID=44712850

Family Applications (3)

Application Number Title Priority Date Filing Date
DK11763476.6T DK2553100T3 (da) 2010-03-31 2011-03-31 Gensplejsning af ikke-humane dyr til frembringelse af kimære antistoffer
DK17178088.5T DK3248462T3 (da) 2010-03-31 2011-03-31 Genmodificering af mus til fremstilling af kimære antifstoffer
DK17178066.1T DK3251503T3 (da) 2010-03-31 2011-03-31 Genetisk modificering af mus til fremstilling af kimære antistoffer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
DK11763476.6T DK2553100T3 (da) 2010-03-31 2011-03-31 Gensplejsning af ikke-humane dyr til frembringelse af kimære antistoffer

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK17178066.1T DK3251503T3 (da) 2010-03-31 2011-03-31 Genetisk modificering af mus til fremstilling af kimære antistoffer

Country Status (11)

Country Link
US (16) US9580491B2 (da)
EP (5) EP4345164A3 (da)
KR (7) KR102004106B1 (da)
AU (1) AU2011234988B2 (da)
CA (3) CA3006810C (da)
DK (3) DK2553100T3 (da)
ES (1) ES2641920T3 (da)
LT (2) LT3248462T (da)
NZ (1) NZ601171A (da)
PL (1) PL2553100T3 (da)
WO (1) WO2011123708A2 (da)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102362774B1 (ko) 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
EP4345164A3 (en) 2010-03-31 2024-06-26 Ablexis, LLC Genetic engineering of non-human animals for the production of chimeric antibodies
CA2806233C (en) 2010-07-26 2021-12-07 Trianni, Inc. Transgenic animals and methods of use
US10662256B2 (en) 2010-07-26 2020-05-26 Trianni, Inc. Transgenic mammals and methods of use thereof
US10793829B2 (en) 2010-07-26 2020-10-06 Trianni, Inc. Transgenic mammals and methods of use thereof
US9920110B2 (en) 2011-03-09 2018-03-20 Cell Signaling Technology, Inc. Methods and reagents for creating monoclonal antibodies
US20170058029A1 (en) * 2014-05-02 2017-03-02 Chiome Bioscience Inc. Human antibody-producing cell
RU2018110364A (ru) * 2015-08-24 2019-09-26 Трианни, Инк. Усовершенствованное продуцирование иммуноглобулинов
EP3384030A4 (en) 2015-12-03 2019-07-03 Trianni, Inc. IMPROVED IMMUNOGLULINIVITY
EP3411476B1 (en) 2016-02-04 2024-04-24 Trianni, Inc. Enhanced production of immunoglobulins
MX2018014982A (es) 2016-06-03 2019-09-18 Regeneron Pharma Animales no humanos que expresan desoxinucleotidil transferasa terminal exogena.
GB2561352B (en) * 2017-04-10 2023-01-18 Genome Res Ltd Animal models and therapeutic molecules
ES2961713T3 (es) 2017-09-29 2024-03-13 Regeneron Pharma Roedores que expresan el complejo C1Q humanizado
WO2019182751A1 (en) * 2018-03-21 2019-09-26 Crystal Bioscience Inc. Transgenic chicken that produces human antibodies
BR112020019026A2 (pt) 2018-03-24 2020-12-29 Regeneron Pharmaceuticals, Inc. Animal não humano geneticamente modificado, métodos para produzir o animal não humano geneticamente modificado, para geração de uma proteína de ligação a antígeno, para obtenção de um ácido nucleico, e, para obtenção de uma célula que expressa um domínio variável de cadeia pesada de imunoglobulina humana e/ou um domínio variável de cadeia leve de imunoglobulina humana, método in vitro de produção de um domínio variável de imunoglobulina humana, ácido nucleico, célula hospedeira, célula isolada, e, domínio variável de cadeia pesada de imunoglobulina humana
CN108486125B (zh) * 2018-03-27 2024-01-05 重庆金迈博生物科技有限公司 一种核酸分子及其在制备人源单域抗体中的应用
WO2019224579A1 (en) 2018-05-23 2019-11-28 Arcelormittal A method for the manufacture of reduced graphene oxide from electrode graphite scrap
US20190380316A1 (en) 2018-06-14 2019-12-19 Regeneron Pharmaceuticals, Inc. Non-human animals capable of engineered dh-dh rearrangement and uses thereof
AU2020322222A1 (en) 2019-07-26 2022-03-24 Janssen Biotech, Inc. Proteins comprising kallikrein related peptidase 2 antigen binding domains and their uses
UY38800A (es) 2019-07-26 2021-01-29 Janssen Biotech Inc Receptor de antígeno quimérico (car) anti-hk2
EP4069722A1 (en) 2019-12-02 2022-10-12 Regeneron Pharmaceuticals, Inc. Peptide-mhc ii protein constructs and uses thereof
JP2023528350A (ja) 2020-05-27 2023-07-04 ヤンセン バイオテツク，インコーポレーテツド Ｃｄ３抗原結合ドメインを含むタンパク質及びその使用
WO2022056276A1 (en) 2020-09-11 2022-03-17 Regeneron Pharmaceuticals, Inc. Identification and production of antigen-specific antibodies
CA3205586A1 (en) 2020-12-16 2022-06-23 Voyager Therapeutics, Inc. Tau binding compounds
JP2024500399A (ja) 2020-12-16 2024-01-09 リジェネロン・ファーマシューティカルズ・インコーポレイテッド ヒト化Ｆｃアルファ受容体を発現するマウス
MX2023007401A (es) 2020-12-23 2023-07-06 Regeneron Pharma Acidos nucleicos que codifican anticuerpos modificados por anclaje y usos de los mismos.
WO2022162549A2 (en) 2021-01-27 2022-08-04 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
IL306108A (en) 2021-03-24 2023-11-01 Janssen Biotech Inc Trispecific antibodies targeting CD79b, CD20 and CD3
PE20240727A1 (es) 2021-08-27 2024-04-15 Janssen Biotech Inc Anticuerpos anti-psma y usos de estos
WO2023046322A1 (en) 2021-09-24 2023-03-30 Janssen Pharmaceutica Nv Proteins comprising cd20 binding domains, and uses thereof
WO2023144723A1 (en) 2022-01-26 2023-08-03 Janssen Biotech, Inc. Immunoconjugates comprising kallikrein related peptidase 2 antigen binding domains and their uses
WO2023250388A1 (en) 2022-06-22 2023-12-28 Voyager Therapeutics, Inc. Tau binding compounds
WO2024092038A2 (en) 2022-10-25 2024-05-02 Ablexis, Llc Anti-cd3 antibodies
WO2024107731A2 (en) 2022-11-14 2024-05-23 Ablexis, Llc Anti-pd-l1 antibodies

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US1270107A (en) 1917-12-07 1918-06-18 John Latson Boardman Stretcher.
US5204244A (en) 1987-10-27 1993-04-20 Oncogen Production of chimeric antibodies by homologous recombination
WO1990000616A1 (en) * 1988-07-07 1990-01-25 Michael Neumaier Recombinomas
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
FR2646438B1 (fr) 1989-03-20 2007-11-02 Pasteur Institut Procede de remplacement specifique d'une copie d'un gene present dans le genome receveur par l'integration d'un gene different de celui ou se fait l'integration
WO1991000906A1 (en) 1989-07-12 1991-01-24 Genetics Institute, Inc. Chimeric and transgenic animals capable of producing human antibodies
US6689610B1 (en) 1989-08-22 2004-02-10 University Of Utah Research Foundation Cells and non-human organisms containing predetermined genomic modifications and positive-negative selection methods and vectors for making same
US5464764A (en) 1989-08-22 1995-11-07 University Of Utah Research Foundation Positive-negative selection methods and vectors
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
SG48759A1 (en) 1990-01-12 2002-07-23 Abgenix Inc Generation of xenogenic antibodies
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
WO1991019796A1 (en) 1990-06-12 1991-12-26 Baylor College Of Medicine Method for homologous recombination in animal and plant cells
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
EP0814159B1 (en) 1990-08-29 2005-07-27 GenPharm International, Inc. Transgenic mice capable of producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
WO1992003917A1 (en) 1990-08-29 1992-03-19 Genpharm International Homologous recombination in mammalian cells
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US7041871B1 (en) * 1995-10-10 2006-05-09 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
WO1992015694A1 (en) 1991-03-08 1992-09-17 The Salk Institute For Biological Studies Flp-mediated gene modification in mammalian cells, and compositions and cells useful therefor
AU2515992A (en) 1991-08-20 1993-03-16 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
GB9119338D0 (en) 1991-09-10 1991-10-23 Inst Of Animal Physiology And Control of gene expression
EP0746609A4 (en) 1991-12-17 1997-12-17 Genpharm Int NON-HUMAN TRANSGENIC ANIMALS CAPABLE OF PRODUCING HETEROLOGOUS ANTIBODIES
CA2140638C (en) 1992-07-24 2010-05-04 Raju Kucherlapati Generation of xenogeneic antibodies
US6765087B1 (en) 1992-08-21 2004-07-20 Vrije Universiteit Brussel Immunoglobulins devoid of light chains
DE4228162C1 (de) 1992-08-25 1994-01-13 Rajewsky Klaus Dr Verfahren zum Ersetzen homologer Genabschnitte aus Säugern in der Keimbahn von nicht-menschlichen Säugern
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6091001A (en) 1995-03-29 2000-07-18 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
US6130364A (en) 1995-03-29 2000-10-10 Abgenix, Inc. Production of antibodies using Cre-mediated site-specific recombination
CA2219361C (en) 1995-04-27 2012-02-28 Abgenix, Inc. Human antibodies derived from immunized xenomice
AU2466895A (en) 1995-04-28 1996-11-18 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
EP0826696B1 (de) 1996-09-03 2002-05-29 GSF-Forschungszentrum für Umwelt und Gesundheit GmbH Verwendung bi-und trispezifischer Antikörper zur Induktion einer Tumorimmunität
KR100942002B1 (ko) 1996-12-03 2010-02-12 암젠 프레몬트 인코포레이티드 복수의 ｖｈ 및 ｖｋ 부위를 함유하는 사람 면역글로불린 유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된 항체
IL131746A0 (en) 1997-03-14 2001-03-19 Method for integrating genes at specific sites in mammalian cells via homologous recombination and vectors for accomplishing the same
US6774279B2 (en) 1997-05-30 2004-08-10 Carnegie Institution Of Washington Use of FLP recombinase in mice
US6090554A (en) 1997-10-31 2000-07-18 Amgen, Inc. Efficient construction of gene targeting vectors
GB9823930D0 (en) 1998-11-03 1998-12-30 Babraham Inst Murine expression of human ig\ locus
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
US6794132B2 (en) 1999-10-02 2004-09-21 Biosite, Inc. Human antibodies
EP1230269A2 (en) * 1999-11-03 2002-08-14 Maxygen, Inc. Antibody diversity generation
US6852530B2 (en) 2000-04-12 2005-02-08 Dana Farber Cancer Institute, Inc. Self-extinguishing recombinases, nucleic acids encoding them and methods of using the same
AU8470301A (en) 2000-08-03 2002-02-18 Wim-Van Schooten Production of humanized antibodies in transgenic animals
US6911204B2 (en) * 2000-08-11 2005-06-28 Favrille, Inc. Method and composition for altering a B cell mediated pathology
US7105348B2 (en) 2000-10-31 2006-09-12 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6596541B2 (en) * 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US6586251B2 (en) 2000-10-31 2003-07-01 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
CA2463233A1 (en) 2001-06-26 2003-01-09 Genome Biosciences, Llc Gene targeting methods and vectors
EP1539233B1 (en) * 2001-07-12 2011-04-27 FOOTE, Jefferson Super humanized antibodies
FR2827302B1 (fr) 2001-07-13 2003-10-10 Genoway Cellule et animal transgenique modelisant la presentation antigenique humaine et leurs utilisations
US20050118648A1 (en) 2001-09-27 2005-06-02 Limin Li Methods and combinations for gene targeting by homologous recombination
EP1461442B1 (en) 2001-11-30 2017-09-06 Amgen Fremont Inc. Transgenic animals bearing human ig lambda light chain genes
AU2002351233A1 (en) 2001-12-04 2003-06-17 Genome Biosciences, Llc Gene targeting methods and vectors
JP3743394B2 (ja) 2002-05-31 2006-02-08 株式会社村田製作所 赤外線センサおよびそれを用いた電子装置
TW588243B (en) 2002-07-31 2004-05-21 Trek 2000 Int Ltd System and method for authentication
EP1539946A4 (en) 2002-09-09 2006-03-15 California Inst Of Techn METHOD AND COMPOSITIONS FOR PRODUCING HUMANIZED MICE
GB2398784B (en) 2003-02-26 2005-07-27 Babraham Inst Removal and modification of the immunoglobulin constant region gene cluster of a non-human mammal
JP2006520610A (ja) 2003-03-04 2006-09-14 アレクシオン ファーマシューティカルズ， インコーポレイテッド ハイブリッド不変領域を産生するのに用いるベクター
WO2005001087A2 (en) 2003-06-11 2005-01-06 Regeneron Pharmaceuticals, Inc. Methods of modifying genes in eukaryotic cells
CA2532117C (en) * 2003-07-15 2012-07-10 Therapeutic Human Polyclonals, Inc. Humanized immunoglobulin loci
WO2005019463A1 (en) 2003-08-11 2005-03-03 Therapeutic Human Polyclonals, Inc. Improved transgenesis with humanized immunoglobulin loci
FR2861255B1 (fr) 2003-10-24 2006-02-17 Centre Nat Rech Scient Mammifere non-humain transgenique pour la region constante de la chaine lourde des immunoglobulines humaines de classe a et ses applications.
RU2486199C2 (ru) 2003-12-10 2013-06-27 Медарекс, Инк. Выделенное антитело против ip-10, иммуноконъюгат и биспецифическая молекула на его основе, их композиции, способ лечения (варианты), кодирующая молекула нуклеиновой кислоты, соответствующий экспрессионный вектор, клетка-хозяин и гибридома
JP2008517600A (ja) 2004-10-22 2008-05-29 セラピューティック ヒューマン ポリクローナルズ， インコーポレイテッド ヒト以外のトランスジェニック動物における内因性免疫グロブリン発現の抑制
WO2006072803A2 (en) 2005-01-10 2006-07-13 Medical Research Council Antibody
US20080196112A1 (en) * 2005-04-29 2008-08-14 Innate Pharma, S.A. Transgenic Animals and Methods of Making Recombinant Antibodies
SG2014010029A (en) * 2005-08-19 2014-08-28 Abbott Lab Dual variable domain immunoglobin and uses thereof
AU2007235496B2 (en) 2006-03-31 2013-11-21 E. R. Squibb & Sons, L.L.C. Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
ATE536374T1 (de) 2006-09-01 2011-12-15 Therapeutic Human Polyclonals Inc Erhöhte expression von humanem oder humanisiertem immunglobulin bei nicht-humanen transgenen tieren
WO2008090958A1 (ja) 2007-01-24 2008-07-31 Kyowa Hakko Kirin Co., Ltd. ドメイン交換された遺伝子組換え抗体組成物
JP5823690B2 (ja) * 2007-06-01 2015-11-25 オーエムティー，インコーポレイティド 内在性免疫グロブリン遺伝子を阻害し、そして、トランスジェニック・ヒト・イディオタイプ抗体を製造するための組成物及び方法
CA2725169A1 (en) 2008-05-23 2009-11-26 Aliva Biopharmaceuticals, Inc. Method of generating single vl domain antibodies in transgenic animals
WO2009157771A2 (en) 2008-06-27 2009-12-30 Merus B.V. Antibody producing non-human mammals
CN102164676B (zh) 2008-07-10 2014-10-29 菲活机器制造公司 带有分离器的珠磨机
KR102362774B1 (ko) * 2008-09-30 2022-02-15 아블렉시스, 엘엘씨 키메라 항체의 제조를 위한 인간 이외의 포유동물
DK2379727T3 (da) 2008-12-18 2017-01-16 Univ Erasmus Med Ct Rotterdam Ikke-humane transgene dyr der udtrykker humaniserede antistoffer og anvendelse deraf
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9445581B2 (en) 2012-03-28 2016-09-20 Kymab Limited Animal models and therapeutic molecules
CN102638971B (zh) 2009-07-08 2015-10-07 科马布有限公司 动物模型及治疗分子
DK2509409T3 (da) 2009-12-10 2016-11-14 Regeneron Pharma Mus, der producerer tungkædeantistoffer
EP4345164A3 (en) 2010-03-31 2024-06-26 Ablexis, LLC Genetic engineering of non-human animals for the production of chimeric antibodies
NZ605966A (en) * 2010-06-17 2015-04-24 Kymab Ltd Animal models and therapeutic molecules
NZ707198A (en) 2010-06-22 2016-04-29 Regeneron Pharma Mice expressing a light chain with human lambda variable and mouse constant regions
CA2806233C (en) * 2010-07-26 2021-12-07 Trianni, Inc. Transgenic animals and methods of use

Also Published As

Publication number Publication date
US20170188558A1 (en) 2017-07-06
PL2553100T3 (pl) 2018-03-30
US20170190795A1 (en) 2017-07-06
EP2553100B1 (en) 2017-07-05
CA2787498A1 (en) 2011-10-06
US11104744B2 (en) 2021-08-31
US20170181414A1 (en) 2017-06-29
CA3006810C (en) 2022-01-11
US20170190794A1 (en) 2017-07-06
DK2553100T3 (da) 2017-10-23
US20200407466A1 (en) 2020-12-31
EP3248462A1 (en) 2017-11-29
KR20160120794A (ko) 2016-10-18
US10836832B2 (en) 2020-11-17
KR20130018259A (ko) 2013-02-20
US20170190797A1 (en) 2017-07-06
KR20180030942A (ko) 2018-03-26
KR20170042382A (ko) 2017-04-18
CA2787498C (en) 2018-06-26
ES2641920T3 (es) 2017-11-14
KR101830020B1 (ko) 2018-02-19
KR102117771B1 (ko) 2020-06-02
KR102004106B1 (ko) 2019-07-25
US10526420B2 (en) 2020-01-07
US10626188B2 (en) 2020-04-21
CA3006810A1 (en) 2011-10-06
US20130167256A1 (en) 2013-06-27
LT3251503T (lt) 2024-05-10
US10829564B2 (en) 2020-11-10
CA3006800A1 (en) 2011-10-06
US20170218090A1 (en) 2017-08-03
AU2011234988B2 (en) 2014-10-30
KR101667440B1 (ko) 2016-10-18
US20200407465A1 (en) 2020-12-31
AU2011234988A1 (en) 2012-10-18
WO2011123708A2 (en) 2011-10-06
EP4345163A2 (en) 2024-04-03
DK3251503T3 (da) 2024-05-06
US20200407464A1 (en) 2020-12-31
US11352444B2 (en) 2022-06-07
KR20210010942A (ko) 2021-01-28
KR102203727B1 (ko) 2021-01-18
US11242409B2 (en) 2022-02-08
NZ601171A (en) 2014-11-28
US11220555B2 (en) 2022-01-11
US20170190796A1 (en) 2017-07-06
EP3248462B1 (en) 2024-03-13
EP2553100A2 (en) 2013-02-06
US10618977B2 (en) 2020-04-14
CA3006800C (en) 2022-10-04
US20200181285A1 (en) 2020-06-11
LT3248462T (lt) 2024-05-27
US11104743B2 (en) 2021-08-31
KR101831117B1 (ko) 2018-04-04
WO2011123708A3 (en) 2012-01-19
EP3251503B1 (en) 2024-03-20
EP4345164A2 (en) 2024-04-03
EP2553100A4 (en) 2013-10-23
US20200181286A1 (en) 2020-06-11
US9580491B2 (en) 2017-02-28
US20200377619A1 (en) 2020-12-03
KR20180030941A (ko) 2018-03-26
US20210002385A1 (en) 2021-01-07
US10662255B2 (en) 2020-05-26
US20170188557A1 (en) 2017-07-06
US10494445B2 (en) 2019-12-03
EP4345163A3 (en) 2024-06-19
EP3251503A1 (en) 2017-12-06
US10604587B2 (en) 2020-03-31
KR20180018835A (ko) 2018-02-21
EP4345164A3 (en) 2024-06-26

Similar Documents

Publication Publication Date Title
DK3251503T3 (da) Genetisk modificering af mus til fremstilling af kimære antistoffer
CY2017025I2 (el) Αντιδοτα αντιπηκτικων
DK3243526T3 (da) Levering af rna til at udløse flere immunsignalveje
DK2346994T3 (da) Knock-in-mus til fremstilling af kimære antistoffer
CR20130292A (es) Mutantes fc de anticuerpos resistentes a proteasas activas
DK2560683T4 (da) Fremstilling af heteromultimeriske proteiner
DK2435568T3 (da) Samling af syntetiske antistoffer til behandling af sygdom
BR112013033063A2 (pt) conversão catalítica de biomassa
CO6930350A2 (es) Mezclas de cemento-scm de partículas empacadas
BR112013011644A2 (pt) variantes de fc silencioso de anticorpos anti-cd40
DK2813573T1 (da) ADAM6 mus
DK2760994T4 (da) Forbindelser til forøget viral transduktion
DK2818183T3 (da) Antigen-bindende molekyle til at fremme forsvinden af antigen ved hjælp af Fc RIIB
BR112013034009A2 (pt) mundo de presença digital remota simultânea massiva
DK2536915T3 (da) Magnetbaseret redskab til impulsinjektion af væske
DK2885408T3 (da) Digital til biologisk konverter
DK2874506T3 (da) Fremgangsmåde til fremstilling af enzymgranulater
DK2569438T3 (da) Fremgangsmåde til fremstilling af biogas
DK2755481T3 (da) Anvendelse af alginatoligomerer til at forøge virkningerne af svampemidler
BR112014003878A2 (pt) síntese de r-bifenilalaninol
DK2931313T3 (da) Opløsningsformuleringer af manipulerede anti-il-23p19-antistoffer
DK2580124T3 (da) Køretøj til bugsering af et fly
DK2785399T3 (da) Svejsede huskomponenter af en peninjektor
DK2864493T3 (da) Fremstilling af enzymer til lignocellulose biomasse
FR2956419B1 (fr) Elements de construction calorifuges